Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

takara bio

Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes

, 8 June 2021/in E-News /by panglobal

Takara Bio Europe AB (TBEAB) and PanCryos have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucoseresponsive beta cells and is one of several customers in TBEAB’s new out-licensing programme.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/takara-bio.jpg 1769 1770 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-06-08 14:31:242021-06-08 14:34:20Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes

SignalChem enters clinical trial collaboration with Merck to evaluate effect of SLC-391 in combination with pembrolizumab in advanced NSLC

, 8 June 2021/in E-News /by panglobal

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, is collaborating with Merck (MSD) through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-06-08 14:28:232021-06-08 14:29:00SignalChem enters clinical trial collaboration with Merck to evaluate effect of SLC-391 in combination with pembrolizumab in advanced NSLC
Therapeutics

Phico Therapeutics awarded up to $18.2 million to advance SASPject antibacterial therapy through Phase 1 clinical trials

, 8 June 2021/in E-News /by panglobal

Phico Therapeutics, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to US$18.2 million from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/Therapeutics.jpg 687 1021 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-06-08 14:25:382021-06-08 14:26:10Phico Therapeutics awarded up to $18.2 million to advance SASPject antibacterial therapy through Phase 1 clinical trials
hr PAN0065 CLI magazine nr

ENPICOM and Viroclinics-DDL receive joint MIT Zuid subsidy to accelerate and improve antibody and vaccine discovery and development

, 8 June 2021/in E-News /by panglobal

Viroclinics-DDL, a Contract Research Organization specialized in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have received approval of their joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines ‘wet-lab’ (in vitro) diagnostic and high-throughput sequencing expertise of Viroclinics-DDL and ‘dry-lab’ (in […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/hr-PAN0065-CLI-magazine-nr.jpg 1493 1446 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-06-08 14:22:022021-06-08 14:22:02ENPICOM and Viroclinics-DDL receive joint MIT Zuid subsidy to accelerate and improve antibody and vaccine discovery and development

Oxford University and Prenetics collaborate to scale rapid testing tech globally

, 8 June 2021/in E-News /by 3wmedia

The University of Oxford, Prenetics Limited, a global leader in diagnostics and genetic testing, and Oxford Suzhou Centre for Advanced Research (OSCAR) have signed collaboration agreements to further develop the award-winning OxLAMP technology, a rapid, molecular testing technology for infectious diseases.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-06-08 14:18:022021-06-08 14:18:02Oxford University and Prenetics collaborate to scale rapid testing tech globally
Celonic CHO

Celonic Group, University College London in partnership to produce protein therapeutics using CHOvolution platform

, 8 June 2021/in E-News /by panglobal

Celonic Group, a Swiss-German contract development and manufacturing organization, and University College London (UCL), UK, have set up a partnership to enable UCL to use Celonic’s CHOvolution cell expression platform for the production of therapeutic protein candidates.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/Celonic_CHO-scaled.jpg 1832 2560 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-06-08 14:15:112021-06-08 14:15:11Celonic Group, University College London in partnership to produce protein therapeutics using CHOvolution platform
liam taylor

Axol Bioscience and Censo Biotechnologies merge to boost iPSC-related technologies

, 8 June 2021/in E-News /by 3wmedia

Axol Bioscience, a provider of iPSC-derived cells, media, and characterization services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, have merged.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/liam-taylor.png 298 224 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-06-08 14:11:222021-06-08 14:11:22Axol Bioscience and Censo Biotechnologies merge to boost iPSC-related technologies
lab generic 1

Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test

, 8 June 2021/in E-News /by 3wmedia

Aptamer Group, the developer of diagnostic and therapeutic Optimer reagents, has entered a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/lab-generic_1.jpg 1271 1920 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-06-08 14:06:342021-06-08 14:06:34Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test
Genome Browser 3.7

Qlucore announces extensive upgrade to Qlucore Omics Explorer with ChIP-seq and Biomarker support

, 8 June 2021/in E-News /by panglobal

Qlucore, a leading software provider of powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics, has released Qlucore Omics Explorer (QOE) version 3.7, an extensive upgrade adding features in many different areas to strengthen visual analysis support even further.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/Genome-Browser-3.7.jpg 748 1200 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2021-06-08 11:58:212021-06-09 10:25:35Qlucore announces extensive upgrade to Qlucore Omics Explorer with ChIP-seq and Biomarker support
Lonza PyroTec PRO

Lonza expands automated robotic solution for endotoxin testing

, 8 June 2021/in E-News /by Lonza Verviers Sprl

Lonza has expanded its popular PyroTec PRO Automated Robotic Solution for endotoxin testing. The new PyroWave Reader add-on has been designed specifically for use with the sustainable PyroGene Recombinant Factor C (rFC) Assay.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/06/Lonza-PyroTec-PRO.jpg 1592 2480 Lonza Verviers Sprl https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png Lonza Verviers Sprl2021-06-08 11:53:552021-06-09 10:25:46Lonza expands automated robotic solution for endotoxin testing
Page 68 of 227«‹6667686970›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
13 November 2025

New Chromsystems Product for Antiepileptic Drugs Testing

11 November 2025

Trusted analytical solutions for reliable results

10 November 2025

Chromsystems | Therapeutic Drug Monitoring by LC-MS/MS

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription